Skip to main content
PrintBio has joined a federal consortium led by WFIRM to receive up to 24.8 million USD from ARPA-H for bioprinting vascularized kidney tissue.
Partnership
1 min read

PrintBio has joined a federal consortium led by WFIRM to receive up to 24.8 million USD from ARPA-H for bioprinting vascularized kidney tissue.

PrintBio
PrintBio

Application

Originally reported by VoxelMatters

PrintBio has joined a federal consortium led by WFIRM to receive up to 24.8 million USD from ARPA-H for bioprinting vascularized kidney tissue. This five-year initiative will scale cell manufacturing and biofabrication to create on-demand organs from a patient’s own cells. By integrating programmable bioresorbable platforms, the program shifts the industry from anatomical models to functional, immunocompetent organ production. This investment marks a systemic move toward solving organ shortages via additive manufacturing. 🏥🧬 #bioprinting #additivemanufacturing #medtech #regenerativemedicine

Explore PrintBioRead Original

How This Connects

6 related events
  1. Same pattern

    Cyfuse and NSK announce the development of a new bio-3D printer designed for the commercial production of regenerative medicine and 3D cell products.

  2. Same pattern

    EPFL researchers developed a room-temperature 3D printing process using enzyme-driven mineralization to create bone scaffolds that become load-bearing within 7 days.

  3. Same pattern

    Auxilium Biotechnologies is partnering with Starlab Space to deploy the AMP-1 bioprinting platform for scalable medical manufacturing in low Earth orbit.

  4. This article

    PrintBio has joined a federal consortium led by WFIRM to receive up to 24.8 million USD from ARPA-H for bioprinting vascularized kidney tissue.

  5. Same pattern

    A consortium led by Wake Forest and Rice University secured 24.8 million dollars from ARPA-H to develop bioprinted, vascularized kidney tissues.

  6. Same pattern

    Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapies for Type 1 diabetes.

  7. Same pattern

    Nanochon secured $4.1M in funding to launch first-in-human trials for its 3D-printed knee implant.